Primul medicament care impiedica patrunderea HIV in celule - autorizat pe piata europeana
'%20fill='%23FBBC05'%20d='M0%2037V11l17%2013z'/%3e%3cpath%20clip-path='url(%23b)'%20fill='%23EA4335'%20d='M0%2011l17%2013%207-6.1L48%2014V0H0z'/%3e%3cpath%20clip-path='url(%23b)'%20fill='%2334A853'%20d='M0%2037l30-23%207.9%201L48%200v48H0z'/%3e%3cpath%20clip-path='url(%23b)'%20fill='%234285F4'%20d='M48%2048L17%2024l-4-3%2035-10z'/%3e%3c/svg%3e){kind=small}
'%20inkscape:export-filename='C:\Users\GioSal\Desktop\Google%20Discover%20(truT)%20326.png'%20inkscape:export-xdpi='195.8'%20inkscape:export-ydpi='195.8'%3e%3cdefs%20id='defs14'%20/%3e%3csodipodi:namedview%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1'%20objecttolerance='10'%20gridtolerance='10'%20guidetolerance='10'%20inkscape:pageopacity='0'%20inkscape:pageshadow='2'%20inkscape:window-width='1920'%20inkscape:window-height='1057'%20id='namedview12'%20showgrid='false'%20inkscape:zoom='3.280264'%20inkscape:cx='10.573959'%20inkscape:cy='124.53611'%20inkscape:window-x='-8'%20inkscape:window-y='-8'%20inkscape:window-maximized='1'%20inkscape:current-layer='svg10'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20/%3e%3cmetadata%20id='metadata2'%3e%20Created%20by%20potrace%201.15,%20written%20by%20Peter%20Selinger%202001-2017%20%3crdf:RDF%3e%3ccc:Work%20rdf:about=''%3e%3cdc:format%3eimage/svg+xml%3c/dc:format%3e%3cdc:type%20rdf:resource='http://purl.org/dc/dcmitype/StillImage'%20/%3e%3cdc:title%3e%3c/dc:title%3e%3c/cc:Work%3e%3c/rdf:RDF%3e%3c/metadata%3e%3cpath%20style='fill:%23fbbc01;fill-opacity:1;stroke:none;stroke-width:0.1'%20inkscape:connector-curvature='0'%20id='path6'%20d='m%2017.485799,17.161672%20-7.199999,7.3%2012.699999,12.7%2012.8,12.8%20h%20-17.8%20H%200%20v%2010%2010%20h%2017.985799%2017.8%20l%207.2,-7.2%207.3,-7.2%20v%20-10.1%20-10%20l%20-12.8,-12.8%20-12.7,-12.7000001%20z'%20sodipodi:nodetypes='ccccccccccccccccc'%20/%3e%3cpath%20style='fill:%23eb4435;fill-opacity:1;stroke:none;stroke-width:0.09999999'%20inkscape:connector-curvature='0'%20id='path6-5'%20d='m%2050.05716,27.699999%20-0.01515,27.760627%202.815154,-2.760627%20c%202.777219,-2.723427%202.9,-2.7%2017.2,-2.7%20h%2014.499999%20l%2012.7,-12.7%20L%20110.05716,24.5%20l%20-7.2,-7.2%20-7.299997,-7.3000001%20-12.7,12.6999991%20-12.799999,12.8%20v%20-17.8%20V%200%20h%20-10%20-10%20z'%20sodipodi:nodetypes='ccsscccccccccccc'%20/%3e%3cpath%20style='fill:%234886f4;fill-opacity:1;stroke:none;stroke-width:0.10002016'%20inkscape:connector-curvature='0'%20id='path6-2'%20d='m%2052.636899,52.666772%20c%20-1.087936,1.139283%20-3.026919,2.966444%20-3.435046,4.11722%20-0.379981,1.071417%200.733956,1.44349%200.733956,3.08278%20v%204.5%20l%2022.709161,22.699999%2022.809202,22.799989%207.202908,-7.2%207.30294,-7.299989%20-12.705122,-12.7%20-12.805166,-12.799999%20h%2017.807188%2017.70714%20v%20-10%20-10%20H%2087.651024%2055.337988%20Z'%20sodipodi:nodetypes='csscccccccccccccc'%20/%3e%3cpath%20style='fill:%2338a752;fill-opacity:1;stroke:none;stroke-width:0.10003133'%20inkscape:connector-curvature='0'%20id='path6-7'%20d='m%2029.872141,75.638078%20-19.799999,19.812414%207.2,7.304568%207.3,7.20452%2012.699999,-12.707959%2012.8,-12.808026%20v%2017.811155%2017.7111%20h%2010%2010%20V%20102.15469%2084.443595%20l%20-10,-10.006268%20c%20-9.2,-9.105706%20-9.778745,-10.287283%20-10.078745,-14.28979%20l%200.04861,-4.686911%20z'%20sodipodi:nodetypes='cccccccccccccccc'%20/%3e%3c/svg%3e){kind=small}
Comisia Europeana a autorizat, saptamana trecuta, comercializarea unui nou tratament pentru SIDA, releva un articol aparut in ultima editie a saptamanalului francez "L'Express", citata de Rompres.
Comisia Europeana a autorizat, saptamana trecuta, comercializarea unui nou tratament pentru SIDA, releva un articol aparut in ultima editie a saptamanalului francez "L'Express", citata de Rompres. Este vorba despre o molecula care impidica patrunderea virusului HIV in celulele de sange ale persoanelor infectate. Testat pe un numar de 1.000 de pacienti din diverse colturi ale lumii, medicamentul numit Enfurvitide a dat rezultate promitatoare, cu un regres al bolii de aproape un an. In special insa, el pare a fi eficient si la bolnavii aflati in fata unui esec terapeutic, adica in cazul carora nici un alt medicament nu mai are efect. Pe de alta parte, modul sau de administrare este greoi, fiind necesare doua injectii zilnice, cu reactii locale dureroase si cu "o rata marita a infectiilor bacteriene, in principal a pneumoniilor", iar costul trece de 19.000 de dolari anual.
Se încarcă comentariile...
